IRCT20200329046892N3.

Methods	Trial design: double‐blind RCT with 2 parallel arms Type of record: trial register entry Sample size: 60 Setting: inpatient Country: Iran Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: IRCT20200329046892N3 Date of registration: 29 March 2021
Participants	Inclusion criteria All COVID‐19 patients admitted to the coronavirus ward of Razi Hospital in Rasht for period of April to July 2021 ≥ 18 years old Patients admitted with fever (oral temperature greater than 37.2 °C), dry cough, severe tiredness or dyspnea positive PCR or lung involvement on chest X‐ray/CT scan Exclusion criteria Lack of informed consent Lack of patient co‐operation Pulmonary embolism or intravascular thrombosis Any major drug interaction between routine patient's drugs with any of the study drugs Pregnancy and lactation Simultaneous presence in other research study
Interventions	Details of intervention Type and dose: ivermectin, 12 mg once/day for 2 days + standard care for 10 days Route of administration: oral Treatment details of control group placebo once/day for 2 days + standard care for 10 days Concomitant therapy: standard of care (no details provided) administered in both study arms
Outcomes	Primary study outcome Time required to improve clinical symptoms within 10 days of treatment start Relevant review outcomes planned Mortality Additional study outcomes Body temperature Heart rate Blood pressure Respiration rate Duration of hospitalization SpO2 Creatine phosphokinase, before intervention, day 5 and 10 CRP, before intervention, day 5 and 10 ESR, before intervention, day 5 and 10
Notes	Reason for awaiting classification: study completed, but results not published yet Recruitment status: completed Prospective completion date: July 2021, study completed Planned completion date more than 6 months ago: yes Date last update posted: 29 March 2021 Sponsor/funding: Rasht University of Medical Sciences